Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 21 (3) , 388-401
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2011
- NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer CellsCancer Research, 2010
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphomaBlood, 2010
- Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescenceNature, 2010
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In SituMolecular Cell, 2010
- Development of a charcoal paper adenosine triphosphate:pyrophosphate exchange assay: Kinetic characterization of NEDD8 activating enzymeAnalytical Biochemistry, 2009
- ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK InhibitorsBiochemistry, 2009
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- The Leukotriene LTD4 Receptor Antagonist Mk571 Specifically Modulates MRP Associated Multidrug ResistanceBiochemical and Biophysical Research Communications, 1995